Showing 957 results
-
Press release /Basel, October 28, 2025 - Novartis today announced that it has successfully completed its acquisition of Tourmaline Bio, Inc. (“Tourmaline”). With the completion of the acquisition, shares of common…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Novartis and Roche agree a bilateral transaction for the sale of Roche bearer shares held by Novartis for a total consideration of USD 20.7 billion…
-
Press release /Submission is supported by comprehensive package of analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc.Breast cancer is one of most common types of…
-
Press release /Novartis is collaborating with Hewlett Packard Enterprise to accelerate the use of data and digital technologies within its efforts to reimagine global health and improve access to healthcare and…
-
Press release /Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030Enables manufacturing of medicines across company’s main therapeutic…
-
Ad hoc release /Transformation to focused medicines company continued with the spin-off of Alcon; commentary below is on continuing operations[2] Continuing operations net sales up 7% (cc[1], +2% USD) driven by…
-
Ad hoc release /Piqray (alpelisib, formerly BYL719) plus fulvestrant nearly doubled median PFS (11.0 vs 5.7 months) in HR+/HER2- advanced breast cancer patients with a PIK3CA mutation compared to fulvestrant alone…
-
Press release /Zolgensma® (onasemnogene abeparvovec) is conditionally approved in Europe for the treatment of patients with spinal muscular atrophy (SMA) and a clinical diagnosis of SMA Type 1; or SMA patients with…
-
Press release /Data from the comprehensive clinical program show AMG 334 (erenumab) is safe and effective at preventing migraine in patients with 4 or more migraine days per month AMG 334 (erenumab)…
-
Press release /Phase III PSMAfore trial with Pluvicto™ met its primary endpoint of radiographic progression-free survival (rPFS) with a HR of 0.411; Pluvicto more than doubled median rPFS to 12.0 months per updated…